CRCM LP
ANAB icon

CRCM LP’s AnaptysBio ANAB Stock Holding History

CRCM LP’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$9.1M Buy
+181,114
New +$10.2M 5.05% 4

Other funds holding ANAB

State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Sanofi
Sanofi Paris, France $630M AUM 104.49% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 38.25% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return
Diamond Hill Capital Management
Diamond Hill Capital Management Columbus, Ohio $9.18B AUM 10.37% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $179B AUM 29.92% 1-Year Est. Return

CRCM LP's ANAB Position: Q3 2026 in Review

CRCM LP opened a new position in AnaptysBio (ANAB) in Q3 2026: 181,114 shares worth $9.1M. The stake represents 5.05% of the portfolio and ranks #4 among its holdings.

118 funds tracked by Wall St. Rank hold ANAB as of Q3 2026.

  • CRCM LP held 181,114 shares of AnaptysBio worth $9.1M as of Q3 2026.
  • AnaptysBio was a new CRCM LP position in Q3 2026.
  • AnaptysBio made up 5.05% of CRCM LP's portfolio in Q3 2026, its #4 holding.
  • 118 funds tracked by Wall St. Rank held AnaptysBio as of Q3 2026.

Based on CRCM LP's 13F filing for Q3 2026, filed 12 Nov 2026.